Details of the Drug Reposition

General Information of This Drug (ID: DM94IQ3)

Drug Name
Telcyta canfosfamide   DM94IQ3

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 3 [1]
Mantle cell lymphoma DISFREOV 2A85.5 Phase 3 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 3 [1]
------------------------------------------------------------------------------------

References

1 Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.Eur J Cancer. 2009 Sep;45(13):2324-32.